Of note, recent combination therapy of blinatumomab with allo-SCT successfully induces a durable remission in the majority of TCF3-HLF-positive ALL patients resistant to a conventional chemotherapy [27]. This evidence concerns the gene HLF and acute lymphoblastic leukemia.